ENTA
EnantaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade D from latest DB weights. Momentum 60.0 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
60
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $21.57
Why
Momentum60 · Δ7d -6.7
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
60
40% active weight
Current posture
7d trendImproving
Δ7d
-6.7
Δ21d
+58.6
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 60.0 / Value 41.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$382.67M
Beta
0.99
Shares Out
29.08M
P/E (TTM) · Derived
-3.4
P/S (TTM)
6.15
P/FCF (TTM) · Derived
-60.12
Rev YoY
+15.0%
EPS YoY
-57.5%
Gross Margin
+92.9%
Op Margin
-130.7%
Net Debt
$12.19M
Current Ratio
3.84
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology